Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APRNYSE:BVSNASDAQ:DSGNNYSE:TBANASDAQ:TDUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPRApria$37.50$37.45$22.36▼$40.00$1.34BN/A682,285 shsN/ABVSBioventus$7.14+4.3%$6.72$5.73▼$14.38$586.84M0.84432,127 shs172,470 shsDSGNDesign Therapeutics$3.77+2.4%$3.84$2.60▼$7.77$214.02M1.56177,098 shs47,533 shsTBAThoma Bravo Advantage$9.61$9.72▼$13.19$1.04BN/A1.40 million shs1.83 million shsTDUPThredUp$7.89+4.2%$7.05$0.50▼$8.75$945.98M1.731.31 million shs1.28 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPRApria0.00%0.00%0.00%0.00%0.00%BVSBioventus0.00%+5.52%+9.40%-14.24%+21.29%DSGNDesign Therapeutics0.00%+5.60%-8.05%+10.88%+18.18%TBAThoma Bravo Advantage0.00%0.00%0.00%0.00%0.00%TDUPThredUp0.00%+5.91%+3.14%+200.00%+378.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPRApriaN/AN/AN/AN/AN/AN/AN/AN/ABVSBioventus2.7285 of 5 stars3.30.00.00.00.04.21.3DSGNDesign Therapeutics0.3795 of 5 stars1.01.00.00.00.62.50.6TBAThoma Bravo AdvantageN/AN/AN/AN/AN/AN/AN/AN/ATDUPThredUp1.0676 of 5 stars1.33.00.00.00.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPRApria 0.00N/AN/AN/ABVSBioventus 2.67Moderate Buy$14.33100.63% UpsideDSGNDesign Therapeutics 2.00Hold$4.006.10% UpsideTBAThoma Bravo Advantage 0.00N/AN/AN/ATDUPThredUp 2.67Moderate Buy$7.25-8.11% DownsideCurrent Analyst Ratings BreakdownLatest DSGN, APR, TBA, TDUP, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.005/6/2025TDUPThredUpWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $7.505/6/2025TDUPThredUpTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.004/30/2025TDUPThredUpWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$3.00 ➝ $6.004/28/2025TDUPThredUpTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$3.00 ➝ $6.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPRApria$1.15B1.17$5.27 per share7.12$1.12 per share33.48BVSBioventus$567.70M1.03$0.57 per share12.58$2.80 per share2.55DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/ATBAThoma Bravo AdvantageN/AN/AN/AN/AN/AN/ATDUPThredUp$260.03M3.59N/AN/A$0.48 per share16.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPRApria$64.88MN/A0.0020.49N/A5.66%586.18%9.23%N/ABVSBioventus-$156.23M-$0.48N/A15.53N/A-7.11%15.61%4.01%N/ADSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)TBAThoma Bravo Advantage-$30KN/A0.00N/AN/AN/AN/AN/AN/ATDUPThredUp-$76.99M-$0.58N/AN/AN/A-22.41%-77.03%-26.15%8/4/2025 (Estimated)Latest DSGN, APR, TBA, TDUP, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/5/2025Q1 2025TDUPThredUp-$0.07-$0.04+$0.03-$0.04$67.54 million$71.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPRApriaN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ATBAThoma Bravo AdvantageN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPRApria8.581.091.06BVSBioventus1.851.410.99DSGNDesign TherapeuticsN/A28.3728.37TBAThoma Bravo AdvantageN/A1.381.38TDUPThredUp0.310.920.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPRApriaN/ABVSBioventus62.94%DSGNDesign Therapeutics56.64%TBAThoma Bravo AdvantageN/ATDUPThredUp89.08%Insider OwnershipCompanyInsider OwnershipAPRApriaN/ABVSBioventus33.00%DSGNDesign Therapeutics31.20%TBAThoma Bravo AdvantageN/ATDUPThredUp27.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPRApria6,08035.65 millionN/ANot OptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableTBAThoma Bravo AdvantageN/A102.40 millionN/ANot OptionableTDUPThredUp2,890118.25 million86.32 millionOptionableDSGN, APR, TBA, TDUP, and BVS HeadlinesRecent News About These CompaniesQ1 Earnings Review: Apparel and Accessories Stocks Led by ThredUp (NASDAQ:TDUP)July 4 at 9:56 PM | msn.com5 Revealing Analyst Questions From ThredUp’s Q1 Earnings CallJune 27, 2025 | msn.comApparel and Accessories Stocks Q1 Recap: Benchmarking Stitch Fix (NASDAQ:SFIX)June 25, 2025 | msn.comThredUp (NASDAQ:TDUP) Stock Price Down 4.9% - Here's What HappenedJune 24, 2025 | marketbeat.comUnpacking Q1 Earnings: Under Armour (NYSE:UAA) In The Context Of Other Apparel and Accessories StocksJune 20, 2025 | msn.comThredUp (TDUP): Buy, Sell, or Hold Post Q1 Earnings?June 18, 2025 | msn.comThredUp (NASDAQ:TDUP) Sets New 12-Month High - Here's What HappenedJune 17, 2025 | marketbeat.com5 *GIANT* CHRISTMAS HACKS in 5 minutes or less! ⛄️ ️ (don’t miss!)June 17, 2025 | msn.comUnpacking Q1 Earnings: Figs (NYSE:FIGS) In The Context Of Other Apparel and Accessories StocksJune 17, 2025 | msn.comMarvell Technology, onsemi, ThredUp, Wayfair, and Teradyne Shares Are Soaring, What You Need To KnowJune 16, 2025 | msn.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ThredUp Inc. (NASDAQ: TDUP)June 16, 2025 | prnewswire.comQ1 Earnings Highlights: Levi's (NYSE:LEVI) Vs The Rest Of The Apparel and Accessories StocksJune 14, 2025 | finance.yahoo.comSimplicity Wealth LLC Purchases New Holdings in ThredUp Inc. (NASDAQ:TDUP)June 14, 2025 | marketbeat.com81,417 Shares in ThredUp Inc. (NASDAQ:TDUP) Purchased by Millennium Management LLCJune 14, 2025 | marketbeat.comTwo Sigma Investments LP Raises Position in ThredUp Inc. (NASDAQ:TDUP)June 13, 2025 | marketbeat.comThredUp (NASDAQ:TDUP) Reaches New 52-Week High - Here's What HappenedJune 10, 2025 | marketbeat.comTwo Sigma Advisers LP Purchases 92,800 Shares of ThredUp Inc. (NASDAQ:TDUP)June 8, 2025 | marketbeat.comWall Street Zen Upgrades ThredUp (NASDAQ:TDUP) to BuyJune 7, 2025 | marketbeat.comSquarepoint Ops LLC Lowers Position in ThredUp Inc. (NASDAQ:TDUP)June 6, 2025 | marketbeat.comThredUp (NASDAQ:TDUP) Shares Gap Down - Time to Sell?June 5, 2025 | marketbeat.comThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains...May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseThe Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackSpotify's Massive Rally: Can New Features Sustain the Momentum?By Nathan Reiff | June 27, 2025View Spotify's Massive Rally: Can New Features Sustain the Momentum?DSGN, APR, TBA, TDUP, and BVS Company DescriptionsApria NYSE:APRApria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.Bioventus NYSE:BVS$7.14 +0.29 (+4.29%) As of 07/3/2025 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Design Therapeutics NASDAQ:DSGN$3.77 +0.09 (+2.45%) As of 07/3/2025 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Thoma Bravo Advantage NYSE:TBAThoma Bravo Advantage does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Chicago, Illinois.ThredUp NASDAQ:TDUP$7.89 +0.32 (+4.23%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$7.89 0.00 (0.00%) As of 07/3/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
